More recently, a phase Ib trial investigated the combination of CIK cells, platinum-based chemotherapy, and the anti-PD-1 antibody sintilimab in treatment-naïve stage IIIB-IV NSCLC (NCT03987867) (58). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.